you've noted the big news here, but not quite pinned it. The amazing issue here is that the results have demonstrated 225 is effective even after the onset of sickness. This is unique from all other C19 drugs, even Paxlovid, that requires it to be taken prior to the onset of sickness.
Of course, this is still on an animal model, and yet to be demonstrated in humans. But knowing what has been achieved in HIV and how hidden reservoirs are cleared, coupled with this advancement in C19 mice, then the human trial is very likely to show the same.
This is what 'sets it apart.' The increased 'therapeutic window'
